MedTrace Logo

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT04677179 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2023-09-05

Study results available
· View outcomes & findings →

Summary

The reason for this study is to determine if the study drug LY3471851 is safe and effective in adult participants with active ulcerative colitis (UC). The study treatment will last about 52 weeks.

Conditions

  • Colitis, Ulcerative

Interventions

DRUG

LY3471851

administered SC

DRUG

Placebo

administered SC

Sponsors & Collaborators

Principal Investigators

  • Study Director · Nektar Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2022-08-09
Completion
2022-08-09
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • China
  • Czechia
  • France
  • Georgia
  • Hungary
  • India
  • Israel
  • Japan
  • Latvia
  • Poland
  • Romania
  • Russia
  • Slovakia
  • South Korea
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04677179 on ClinicalTrials.gov